Dev

PKR and danger molecules in Alzheimer’s disease Investments > €500k France Alzheimer’s disease & other dementias 2016    

A new Generation of Drugs for ALzheimer’s disease based on in vitro and in silico experiments of beta-amyloid oligomers and in vivo tests Investments > €500k France Alzheimer’s disease & other dementias 2016    

Modelling multi-factorial neurodegeneration in Parkinson’s disease: removing roadblocks towards the clinic Investments > €500k France Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Validation and Clinical Implementation of Parkinson’s Disease and Breast Cancer Biomarkers for Diagnosis and Treatment Response Monitoring Investments > €500k Finland Parkinson’s disease & PD-related disorders 2016    

Nanoparticle Assisted Brain in vivo Imaging Investments > €500k Finland Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Coupling factor 6, a circulating vasoactive peptide, in Alzheimer’s disease Investments > €500k Finland Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Centre of Excellence in Research on Mitochondria, Metabolism and Disease (FinMIT) Investments > €500k Finland Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

THERAPEUTIC USE OF EPIGENETIC MODULATORS IN ONCOLOGICAL AND NEURODEGENERATIVE DISEASE Investments > €500k Spain Alzheimer’s disease & other dementias 2016    

EPIGENETIC AND ENVIRONMENTAL FACTORS BRACING COGNITIVE IMPAIRMENT AND LATE-ONSET DEPRESSION IN ELDERLY AND EARLY STAGES OF ALZHEIMER DISEASE Investments > €500k Spain Alzheimer’s disease & other dementias 2016    

MOLECULAR LINKS BETWEEN DIABETES AND NEURODEGENERATIVE DISORDERS Investments > €500k Spain Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016